Metabo provides medication tracking and estimation features to help users better understand how GLP-1 medications may behave in the body over time. These estimations are based on established pharmacokinetic principles and publicly available clinical research.
The goal of this feature is to give users a general understanding and visual guidance, not to provide exact or clinically precise measurements.
How the Estimates Work
The medication levels shown in this app are estimates calculated using established pharmacokinetic (PK) principles. They are based on peer-reviewed clinical studies and official clinical pharmacology data, and are intended for informational and motivational purposes only.
These calculations consider several key factors:
- Half-life of the medication
- GLP-1 medications such as semaglutide and tirzepatide remain in the body for several days. The concept of half-life is used to estimate how quickly the medication decreases over time.
- Dosage & Injection History
- The system takes into account the dosage, medication type, and how often the medication is taken, allowing it to estimate accumulation and decline patterns.
- Multiple Injections
- If you have logged multiple doses, the total estimated level is the sum of all active doses still present in your system.
Limitations
These estimations are not personalized medical measurements and may not reflect actual drug levels in the body.
They do not account for:
- Individual metabolism
- Health conditions
- Lifestyle factors
- Other medications or interactions
Because of this, results may vary significantly between individuals.
Medical Disclaimer
Metabo is designed for informational and educational purposes only.
The content and calculations provided in this app:
- Do not constitute medical advice
- Are not intended to diagnose, treat, or prevent any condition
Users should always consult a qualified healthcare professional before making any medical decisions or changes to their treatment.
Sources & References
The information and estimations in Metabo are based on a combination of clinical studies, regulatory data, and publicly available research, including:
- FDA Clinical Pharmacology Review: Tirzepatide (Mounjaro) — NDA 215866. U.S. Food & Drug Administration, 2022.
- FDA Prescribing Information: Semaglutide (Ozempic) — NDA 209637. U.S. Food & Drug Administration, 2017.
- Granhall, C. et al. (2019). Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. Diabetes Therapy. DOI: 10.1007/s13300-019-0581-y
- Overgaard, R.V. et al. (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical Pharmacokinetics. DOI: 10.1007/s40262-021-01025-x
- Additional pharmacokinetic references and GLP-1 research sources used in product development
Transparency Commitment
We aim to ensure that all health-related information in Metabo is clear, transparent, and supported by credible sources. References are provided so users can explore the underlying research if they wish. Individual responses to GLP-1 medications can vary significantly. These estimates are for informational purposes only and must not be considered medical advice. Always consult your healthcare provider for specific guidance regarding your treatment and dosage.
Official Drug Labels & Regulatory Documents
1. FDA Clinical Pharmacology Review: Tirzepatide (Mounjaro) — NDA 215866. U.S. Food & Drug Administration, 2022.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf
2. FDA Prescribing Information: Semaglutide (Ozempic) — NDA 209637. U.S. Food & Drug Administration, 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
Peer-Reviewed Research — Semaglutide
3. Granhall, C. et al. (2019). Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. Diabetes Therapy. DOI: 10.1007/s13300-019-0581-y
https://link.springer.com/article/10.1007/s13300-019-0581-y
4. Overgaard, R.V. et al. (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical Pharmacokinetics. DOI: 10.1007/s40262-021-01025-x
https://link.springer.com/article/10.1007/s40262-021-01025-x
5. Granhall, C. et al. (2019). Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Oral Semaglutide in Healthy Subjects and Subjects with Type 2 Diabetes. Clinical Pharmacokinetics. DOI: 10.1007/s40262-018-0728-4
https://pubmed.ncbi.nlm.nih.gov/30565096/
6. Granhall, C. et al. (2018). Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clinical Pharmacokinetics.
https://pubmed.ncbi.nlm.nih.gov/29623579/
Peer-Reviewed Research — Tirzepatide
7. Schneck, K. et al. (2024). Population Pharmacokinetics of the GIP/GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacology & Therapeutics.
https://pubmed.ncbi.nlm.nih.gov/38356317/
8. Jastreboff, A.M. et al. (2023). Tirzepatide Once Weekly for the Treatment of Obesity in Adults with Type 2 Diabetes (SURMOUNT-2). New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Peer-Reviewed Research — GLP-1 Pharmacokinetics (General)
9. Min, T. et al. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.
https://pubmed.ncbi.nlm.nih.gov/40330819/
10. Cao, Y., Gao, W. & Jusko, W.J. (2012). Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats. American Journal of Physiology. PMC3412591.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3412591/
11. D’Alessio, D.A. (2007). Physiology of the GLP-1 Receptor Agonist. American Journal of Physiology – Regulatory, Integrative and Comparative Physiology. DOI: 10.1152/ajpregu.00911.2006
https://journals.physiology.org/doi/prev/null-aop/abs/10.1152/ajpregu.00911.2006
Industry & App Research
12. Veritas, L. (2025). Are GLP-1 App Medication Charts Reliable? The GLP-1 Effect.
https://glp1effect.com/p/are-glp-1-app-medication-charts-reliable